Zhenying Xu Jiaman Ma Ting Chen Yu Yang
10.3389/fimmu.2022.978266
Front Immunol
2022 Nov 15;13:978266.
rc48-adc antibody-drug conjugates human epidermal growth factor receptor 2 (her2),trastuzumab (herceptin) pembrolizumab urothelial carcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/36458005/
Carcinoma, Transitional Cell / drug therapy Renal Insufficiency Urinary Bladder Neoplasms / drug therapy
Carcinoma, Transitional Cell / drug therapy Renal Insufficiency Urinary Bladder Neoplasms / drug therapy Case Reports Aged Humans Male Positron Emission Tomography Computed Tomography pembrolizumab
PMC9705978
36458005
Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma
2022